Global Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Guide, 2020 - Therapeutics, Drugs, Players, and Developments

News provided by

Mar 25, 2020, 09:15 ET

DUBLIN, March 25, 2020 /PRNewswire/ -- The "Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2020" report has been added to ResearchAndMarkets.com's offering.

This pipeline guide provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 1, 42, 40, 1, 15, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 6, 2, 1, 3 and 1 molecules, respectively.

Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (Oncology).
The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (Oncology)

Key Topics Covered

Introduction
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Development
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics Development
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Drug Profiles
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Product Development Milestones

Companies Mentioned

A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics SA
Affimed GmbH
Agios Pharmaceuticals Inc
AlfaSigma SpA
Alissa Pharma
Angiocrine Bioscience Inc
Anhui Anke Biotechnology (Group) Co Ltd
Apollomics Inc
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Avipep Pty Ltd
Bayer AG
Biohaven Pharmaceutical Holding Company Ltd
Bristol-Myers Squibb Co
Carrick Therapeutics Ltd
Catalent Inc
Cell Medica Ltd
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Cellectis SA
Celleron Therapeutics Ltd
Cellestia Biotech AG
Cellular Biomedicine Group Inc
Celularity Inc
Checkmate Pharmaceuticals Inc
Checkpoint Therapeutics Inc
Chipscreen Biosciences Ltd
Constellation Pharmaceuticals Inc
CSL Ltd
CStone Pharmaceuticals Co Ltd
Curis Inc
Eutilex Co Ltd
Faron Pharmaceuticals Oy
Gibson Oncology LLC
Gilead Sciences Inc
Harbin Gloria Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Inc Ltd
Helocyte Biosciences Inc
HRAIN Biotechnology Co Ltd
Immune Cell Inc
Immunomedics Inc
Incuron LLC
Incyte Corp
Inhibrx Inc
Magenta Therapeutics Inc
Marker Therapeutics Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Miltenyi Biotec GmbH
NantKwest Inc
NewBio Therapeutics Inc
Northlake International LLC
OncoTartis Inc
Protheragen Inc
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
Rhizen Pharmaceuticals SA
Rich Pharmaceuticals Inc
Rizen (Suzhou) Biosciences Co Ltd
Sanofi
Seattle Genetics Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shattuck Labs Inc
Sichuan Kelun Pharmaceutical Co Ltd
SpecificiT Pharma Inc
Stemline Therapeutics Inc
Syndax Pharmaceuticals Inc
Tacitus Therapeutics Inc
TaiGen Biotechnology Co Ltd
Taiwan Liposome Co Ltd
Tessa Therapeutics Pte Ltd
Trillium Therapeutics Inc
Tyme Technologies Inc
Viracta Therapeutics Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd

For more information about this report visit https://www.researchandmarkets.com/r/q28n73

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets